COMPASS Pathways plc (NASDAQ:CMPS) Receives $33.60 Average Target Price from Brokerages

COMPASS Pathways plc (NASDAQ:CMPS) has been given an average rating of “Buy” by the six analysts that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $33.60.

A number of equities research analysts have recently issued reports on the stock. HC Wainwright cut their target price on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday. Finally, Maxim Group decreased their target price on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 1st.

Hedge Funds Weigh In On COMPASS Pathways

A number of large investors have recently bought and sold shares of CMPS. Franklin Resources Inc. raised its position in shares of COMPASS Pathways by 4.4% during the 3rd quarter. Franklin Resources Inc. now owns 295,785 shares of the company’s stock worth $1,810,000 after purchasing an additional 12,599 shares during the period. Green Alpha Advisors LLC bought a new position in COMPASS Pathways during the 3rd quarter worth $99,000. Y Intercept Hong Kong Ltd acquired a new stake in COMPASS Pathways in the third quarter worth $131,000. Geode Capital Management LLC lifted its stake in COMPASS Pathways by 160.3% in the third quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock valued at $266,000 after buying an additional 25,970 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in shares of COMPASS Pathways by 18.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 174,921 shares of the company’s stock valued at $661,000 after acquiring an additional 26,787 shares during the period. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $3.41 on Tuesday. The firm has a market cap of $233.31 million, a price-to-earnings ratio of -1.55 and a beta of 2.27. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average is $4.36 and its two-hundred day moving average is $5.89. COMPASS Pathways has a 52-week low of $3.16 and a 52-week high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.04. During the same quarter in the prior year, the business posted ($0.67) earnings per share. Analysts forecast that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.